There are some Medicare Part D changes 2025 coming to (MAPD/PDP) plans. One of the biggest changes is the discontinuation of the Medicare donut hole in 2025. In January 2024, CMS released a draft of the new Medicare Part D payment policies.
Click here to get more details on the changes coming to prescription drug coverage in 2025
Key points
Removal of the Donut Hole/Gap phase – The coverage gap phase will merge with the former initial coverage phase. This phase will become the “Standard Coverage Phase”.
There will only be 3 coverage phases. They are Deductible, Standard & Catastrophic.
The Out of Pocket (OOP) threshold for each beneficiary is dropping to $2,000 annually.
The end of the Donut Hole/Gap discount program (CGDP) will place more emphasis on the Manufacturer Discount Program. There will be changes to the drugs that are discounted and how they count towards the OOP. This also changes who is responsible for the cost of the drugs beyond a set amount.
Watch a YouTube video on Medicare Part D changes
The drug plans will pay similar amounts as in previous years, although a larger part of their responsibility starts much earlier than in previous years. In other words, drug plans will pay more money on more enrollees overall.
Click here to learn all the details of the Medicare Part D redesign
The new design for prescription coverage consists of three phases of coverage.
- The first phase is the “Annual Deductible Phase”. In this phase enrollees pay 100% of their prescription drug cost until they meet the deductible of $590.
- The second phase is the initial coverage or “Standard Coverage Phase”. This phase was formerly the initial coverage phase merged with the Donut Hole/Gap phase. During this phase, after the enrollee meets the spending threshold (OOP) of $2,000 for CY 2025, they complete this phase and move into the catastrophic phase.
- The third phase is the “Catastrophic Phase”. During this coverage phase, the enrollee does not pay any cost sharing for covered Part D drugs.
Learn about the CMS 2025 proposed rule
It is very likely the added costs drug companies incur will result in either higher Part D plan premiums as well as changes to MAPD plan benefits and/or costs.
Do you have any questions?
Questions and requests
Recent Comments